Needham Maintains Buy on Revolution Medicines, Raises Price Target to $240

Benzinga Newsdesk www.benzinga.com Positive 81.9%

Neg 0% Neu 0% Pos 81.9%

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $236 to $240.